HomeRLF • SWX
add
RELIEF THERAPEUTICS Holding SA
Previous close
CHF 4.13
Day range
CHF 4.15 - CHF 7.24
Year range
CHF 1.06 - CHF 7.24
Market cap
89.30M CHF
Avg Volume
123.06K
P/E ratio
-
Dividend yield
-
Primary exchange
SWX
Financials
Income Statement
Revenue
Net income
| (CHF) | Jun 2024info | Y/Y change |
|---|---|---|
Revenue | 2.83M | 87.03% |
Operating expense | 4.04M | -41.31% |
Net income | -2.28M | 91.93% |
Net profit margin | -80.60 | 95.69% |
Earnings per share | — | — |
EBITDA | -1.27M | 74.88% |
Effective tax rate | -14.01% | — |
Balance Sheet
Total assets
Total liabilities
| (CHF) | Jun 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 10.73M | -16.20% |
Total assets | 70.92M | -43.61% |
Total liabilities | 21.65M | -31.07% |
Total equity | 49.27M | — |
Shares outstanding | 12.55M | — |
Price to book | 1.05 | — |
Return on assets | -7.01% | — |
Return on capital | -9.62% | — |
Cash Flow
Net change in cash
| (CHF) | Jun 2024info | Y/Y change |
|---|---|---|
Net income | -2.28M | 91.93% |
Cash from operations | -1.58M | 69.75% |
Cash from investing | -3.50K | 96.82% |
Cash from financing | -308.00K | -114.76% |
Net change in cash | -1.91M | 40.61% |
Free cash flow | -635.56K | 75.84% |
About
Relief Therapeutics is a Swiss biopharmaceutical company based in Geneva. The company focuses on developing drugs for serious diseases with few or no existing treatment options. Its lead compound, RLF-100, is a synthetic form of a natural peptide that protects the lung. The company was incorporated as Relief Therapeutics Holdings AG and listed on the SIX Swiss Exchange in 2016. Wikipedia
Founded
2013
Website
Employees
36
